{"id":"lurasidone-tablets","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"8-12","effect":"Somnolence"},{"rate":"5-10","effect":"Parkinsonism"},{"rate":"5-8","effect":"Nausea"},{"rate":"5-7","effect":"Agitation"},{"rate":"5-7","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lurasidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT7 receptors, with high binding affinity and selectivity for these targets. This dual antagonism helps modulate neurotransmitter activity implicated in psychotic and mood disorders. The drug has minimal affinity for other receptors, which may contribute to a favorable side-effect profile compared to first-generation antipsychotics.","oneSentence":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:48.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder depression"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT03465787","phase":"PHASE3","title":"A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2018-04-09","conditions":"Schizophrenia","enrollment":210},{"nctId":"NCT05480150","phase":"NA","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-01","conditions":"Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic","enrollment":10000},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03393026","phase":"PHASE4","title":"A Study of Lurasidone HCl in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Standard Chem. & Pharm. Co., Ltd.","startDate":"2018-01-03","conditions":"Schizophrenia","enrollment":54},{"nctId":"NCT02002832","phase":"PHASE3","title":"A Clinical Trial of Lurasidone in Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2013-12","conditions":"Schizophrenia","enrollment":388},{"nctId":"NCT01932541","phase":"PHASE4","title":"Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Mania, Bipolar I, Bipolar II","enrollment":""},{"nctId":"NCT01731119","phase":"PHASE2","title":"Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":9},{"nctId":"NCT01620060","phase":"PHASE1","title":"Lurasidone Pediatric Pharmacokinetics Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-06","conditions":"Schizophrenia, Autism","enrollment":105},{"nctId":"NCT00088634","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-05","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT00790192","phase":"PHASE3","title":"Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia","enrollment":488},{"nctId":"NCT01143090","phase":"PHASE3","title":"A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":149},{"nctId":"NCT00615433","phase":"PHASE3","title":"Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Schizophrenia","enrollment":478},{"nctId":"NCT00044044","phase":"PHASE2","title":"A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-07","conditions":"Schizophrenia","enrollment":356},{"nctId":"NCT00088621","phase":"PHASE2","title":"A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":61},{"nctId":"NCT00044005","phase":"PHASE2","title":"Safety and Tolerability Study of Drug to Treat Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-09","conditions":"Schizophrenia","enrollment":98},{"nctId":"NCT01284517","phase":"PHASE3","title":"Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-11","conditions":"Bipolar Depression","enrollment":356},{"nctId":"NCT01143077","phase":"PHASE3","title":"A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":244},{"nctId":"NCT01074073","phase":"PHASE1","title":"Lithium Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT01082263","phase":"PHASE1","title":"Midazolam Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia Patients","enrollment":24},{"nctId":"NCT01082276","phase":"PHASE1","title":"Rifampin Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Male, Healthy Normal Subjects","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LATUDA"],"phase":"phase_3","status":"active","brandName":"Lurasidone tablets","genericName":"Lurasidone tablets","companyName":"Sumitomo Pharma (Suzhou) Co., Ltd.","companyId":"sumitomo-pharma-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain. Used for Schizophrenia, Bipolar I disorder depression, Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}